• +1-646-491-9876
    • +91-20-67278686

    Search

    Lymphocyte Activation Gene 3 Protein-Pipeline Review H1 2017

    Lymphocyte Activation Gene 3 Protein-Pipeline Review H1 2017

    • Report Code ID: RW0001834354
    • Category Pharmaceuticals
    • No. of Pages 62
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H1 2017

    Summary

    Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) pipeline Target constitutes close to 22 molecules. Out of which approximately 22 molecules are developed by Companies. The latest report Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H1 2017, outlays comprehensive information on the Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.

    Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Lymphocyte-activation gene 3 or LAG-3 is a protein encoded by the LAG3 gene. It is involved in the maturation and activation of dendritic cells and lymphocyte activation. It binds to HLA class-II antigens. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 5, 2, 8 and 5 respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular and Infectious Disease which include indications Solid Tumor, Non-Small Cell Lung Cancer, Autoimmune Disorders, Lymphoma, Melanoma, Advanced Malignancy, Bladder Cancer, Blood Cancer, Cardiovascular Disease, Cervical Cancer, Chronic Inflammation, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Gastric Cancer, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) , Inflammation, Kidney Cancer (Renal Cell Cancer) , Non-Hodgkin Lymphoma, Ovarian Cancer, Plaque Psoriasis (Psoriasis Vulgaris) , Recurrent Glioblastoma Multiforme (GBM) , Refractory Chronic Lymphocytic Leukemia (CLL) , Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL) , Relapsed Multiple Myeloma and Renal Cell Carcinoma.

    Furthermore, this report also reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)
    - The report reviews Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Overview
    Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Companies Involved in Therapeutics Development
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Company
    Crescendo Biologics Ltd
    Enumeral Biomedical Holdings Inc
    GlaxoSmithKline Plc
    Icell Kealex Therapeutics
    Incyte Corp
    MacroGenics Inc
    Merck & Co Inc
    Novartis AG
    Prima BioMed Ltd
    Regeneron Pharmaceuticals Inc
    Sutro Biopharma Inc
    Symphogen A/S
    Tesaro Inc
    Trellis Bioscience Inc
    Xencor Inc
    Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Drug Profiles
    BI-754111 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BMS-986016 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ENUM-006 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IKT-203 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IMP-701 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IMP-731 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IMP-761 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LAG-525 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MGD-013 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MK-4280 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit LAG-3 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit LAG3 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit LAG3 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit PD-1 and LAG-3 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Target CTLA-4 and LAG-3 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Target PD-1 and LAG-3 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Target PD-1 and LAG-3 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein to Replace CD223 for Cardiovascular Disease and Chronic Inflammation - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    REGN-2810 + REGN-3767 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    REGN-3767 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TRL-7117 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TSR-033 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Dormant Products
    Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Product Development Milestones
    Featured News & Press Releases
    May 01, 2017: TESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to the U.S. FDA
    Jan 03, 2017: Prima Announces New Product Candidate IMP761 - A LAG-3 Agonist Antibody
    Aug 25, 2016: European Patent Grants for IMP731 Antibody
    Apr 19, 2016: MacroGenics Presents Data from MGD013 Preclinical Program at AACR Annual Meeting 2016
    Feb 08, 2016: Crescendo Biologics Presents Key Oncology Data on Humabody Drug Conjugates
    Jan 27, 2016: US Patent Grants for IMP731 Antibody
    Aug 14, 2015: Prima Biomed Announces Commencement of Milestones for IMP701 Program
    May 27, 2015: Crescendo Biologics Expands ADC Programmes with Innovate UK Funding Award
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Boehringer Ingelheim GmbH, H1 2017
    Pipeline by Bristol-Myers Squibb Company, H1 2017
    Pipeline by Crescendo Biologics Ltd, H1 2017
    Pipeline by Enumeral Biomedical Holdings Inc, H1 2017
    Pipeline by GlaxoSmithKline Plc, H1 2017
    Pipeline by Icell Kealex Therapeutics, H1 2017
    Pipeline by Incyte Corp, H1 2017
    Pipeline by MacroGenics Inc, H1 2017
    Pipeline by Merck & Co Inc, H1 2017
    Pipeline by Novartis AG, H1 2017
    Pipeline by Prima BioMed Ltd, H1 2017
    Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
    Pipeline by Sutro Biopharma Inc, H1 2017
    Pipeline by Symphogen A/S, H1 2017
    Pipeline by Tesaro Inc, H1 2017
    Pipeline by Trellis Bioscience Inc, H1 2017
    Pipeline by Xencor Inc, H1 2017
    Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Company
    Crescendo Biologics Ltd
    Enumeral Biomedical Holdings Inc
    GlaxoSmithKline Plc
    Icell Kealex Therapeutics
    Incyte Corp
    MacroGenics Inc
    Merck & Co Inc
    Novartis AG
    Prima BioMed Ltd
    Regeneron Pharmaceuticals Inc
    Sutro Biopharma Inc
    Symphogen A/S
    Tesaro Inc
    Trellis Bioscience Inc
    Xencor Inc

    Request for Sample

    Report Url https://www.reportsweb.com//lymphocyte-activation-gene-3-protein-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//lymphocyte-activation-gene-3-protein-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//lymphocyte-activation-gene-3-protein-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments